IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues
- Authors:
- Christoph Burdelski
- Nilofar Jakani-Karimi
- Frank Jacobsen
- Christina Möller-Koop
- Sarah Minner
- Ronald Simon
- Guido Sauter
- Stefan Steurer
- Till S. Clauditz
- Waldemar Wilczak
-
Affiliations: General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg‑Eppendorf, Hamburg, Germany, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany - Published online on: November 2, 2017 https://doi.org/10.3892/or.2017.6072
- Pages: 3-12
-
Copyright: © Burdelski et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Gong Y, Woda BA and Jiang Z: Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol. 21:191–200. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vikesaa J, Hansen TV, Jønson L, Borup R, Wewer UM, Christiansen J and Nielsen FC: RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 25:1456–1468. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Xu H, Bourne PA, Spaulding BO and Wang HL: High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 38:555–563. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Goodman S, Zhang L, Cheng L and Jiang Z: Differential expression of IMP3 between male and female mature teratomas - immunohistochemical evidence of malignant nature. Histopathology. 65:483–489. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, et al: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 16:3499–3506. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lok T, Chen L, Lin F and Wang HL: Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol. 45:394–400. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Damasceno EA, Carneiro FP, Magalhães AV, Carneiro MV, Takano GH, Vianna LM, Seidler HB, Castro TM, Muniz-Junqueira MI, Amorim RF, et al: IMP3 expression in gastric cancer: Association with clinicopathological features and HER2 status. J Cancer Res Clin Oncol. 140:2163–2168. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH and Hsu HC: RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 48:1118–1127. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL and Kwon ED: Oncofetal protein IMP3: A novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 112:2676–2682. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yan J, Wei Q, Jian W, Qiu B, Wen J, Liu J, Fu B, Zhou X and Zhao T: IMP3 predicts invasion and prognosis in human lung adenocarcinoma. Lung. 194:137–146. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS and Owen DA: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 10:592010. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, et al: Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: A retrospective study. Lancet Oncol. 7:556–564. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tosun Yildirim H and Sentürk N: Analysis of IMP3 expression in prostate adenocarcinomas. Turk Patoloji Derg. 28:128–133. 2012.PubMed/NCBI | |
|
Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, et al: Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. BJU Int. 110:63–68. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, Müntener M, Provenzano M, Sulser T, Behnke S, et al: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer. 10:3412010. View Article : Google Scholar : PubMed/NCBI | |
|
Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, Shariat SF, Rübben H and vom Dorp F: Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. Int J Cancer. 135:1596–1604. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kulaçoğlu S and Erkılınç G: Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules. Balkan Med J. 32:30–37. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R and Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol. 20:149–157. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yorukoglu A, Yalcin N, Avci A, Cakalagaoglu F, Yaylali G, Akin F, Haciyanli M and Ozden A: Significance of IMP3, nucleophosmin, and Ki-67 expression in papillary thyroid carcinoma. Int J Surg Pathol. 23:5–12. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jin L, Seys AR, Zhang S, Erickson-Johnson MR, Roth CW, Evers BR, Oliveira AM and Lloyd RV: Diagnostic utility of IMP3 expression in thyroid neoplasms: A quantitative RT-PCR study. Diagn Mol Pathol. 19:63–69. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto H, Arakaki K, Morimatsu K, Zaitsu Y, Fujita A, Kohashi K, Hirahashi M, Motoshita J, Oshiro Y and Oda Y: Insulin-like growth factor II messenger RNA-binding protein 3 expression in gastrointestinal mesenchymal tumors. Hum Pathol. 45:481–487. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cornejo K, Shi M and Jiang Z: Oncofetal protein IMP3: A useful diagnostic biomarker for leiomyosarcoma. Hum Pathol. 43:1567–1572. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, et al: Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol. 66:379–385. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, et al: Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. J Urol. 191:830–841. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Del Gobbo A, Vaira V, Rocco E Guerini, Palleschi A, Bulfamante G, Ricca D, Fiori S, Bosari S and Ferrero S: The oncofetal protein IMP3: A useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung. J Thorac Oncol. 9:1656–1661. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chang S, Oh MH, Ji SY, Han J, Kim TJ, Eom M, Kwon KY, Ha SY, Choi YD, Lee CH, et al: Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations. Pathol Int. 64:607–612. 2014.PubMed/NCBI | |
|
Üçer Ö, Dağli AF, Kiliçarslan A and Artaş G: Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma. Turk Patoloji Derg. 29:94–100. 2013.PubMed/NCBI | |
|
Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Steurer S, Singer JM, Rink M, Chun F, Dahlem R, Simon R, Burandt E, Stahl P, Terracciano L, Schlomm T, et al: MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays. Urol Oncol. 32:1225–1233. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
von Loga K, Kohlhaussen J, Burkhardt L, Simon R, Steurer S, Burdak-Rothkamm S, Jacobsen F, Sauter G and Krech T: FGFR1 amplification is often homogeneous and strongly linked to the squamous cell carcinoma subtype in esophageal carcinoma. PLoS One. 10:e01418672015. View Article : Google Scholar : PubMed/NCBI | |
|
Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK, Klose H, Marx AH, Koops S, Simon R, et al: Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol. 25:1566–1573. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR and Bockhorn M: Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol. 104:140–145. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mina S, Bohn BA, Simon R, Krohn A, Reeh M, Arnold D, Bokemeyer C, Sauter G, Izbicki JR, Marx A, et al: PTEN deletion is rare but often homogeneous in gastric cancer. J Clin Pathol. 65:693–698. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hammer NA, Hansen T, Byskov AG, Rajpert-De Meyts E, Grøndahl ML, Bredkjaer HE, Wewer UM, Christiansen J and Nielsen FC: Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction. 130:203–212. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tang H, Wei Q, Ge J, Jian W, Liu J, Zhong L, Fu B and Zhao T: IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma. Hum Pathol. 44:2167–2172. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pryor JG, Simon RA, Bourne PA, Spaulding BO, Scott GA and Xu H: Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer similar to other high-grade neuroendocrine carcinomas. Hum Pathol. 40:238–243. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Vranic S, Gurjeva O, Frkovic-Grazio S, Palazzo J, Tawfik O and Gatalica Z: IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast. Appl Immunohistochem Mol Morphol. 19:413–416. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chokoeva AA, Ananiev J, Wollina U, Tana C, Lotti T, Cardoso JC and Tchernev G: Imp-3 expression in benign melanocytic nevi, dysplastic nevi and malignant melanoma: preliminary findings in Bulgarian patients. J Biol Regul Homeost Agents. 29:695–699. 2015.PubMed/NCBI | |
|
Shooshtarizadeh T, Nazeri A, Zare-Mirzaie A and Movahedinia S: Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma. Pathol Res Pract. 212:335–339. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee AF, Gown AM and Churg A: IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol. 37:421–426. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda K, Tate G, Suzuki T, Kitamura T and Mitsuya T: IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: The expression profiles of IMP3/L523S in effusion cytology. Hum Pathol. 41:745–750. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA and Xu H: IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 21:431–437. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL and Dresser K: KOC (K homology domain containing protein overexpressed in cancer): A novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 29:188–195. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 19:1262–1270. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G and Gress TM: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 88:95–99. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lu D, Vohra P, Chu PG, Woda B, Rock KL and Jiang Z: An oncofetal protein IMP3: A new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol. 33:521–525. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Szarvas T, vom Dorp F, Niedworok C, Melchior-Becker A, Fischer JW, Singer BB, Reis H, Bánkfalvi Á, Schmid KW, Romics I, et al: High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer. BJU Int. 110:E308–E317. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Findeis-Hosey JJ and Xu H: Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem. 87:24–29. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Li HG, Xia ZS, Lü J and Peng TS: IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: A retrospective study. Chin Med J (Engl). 123:3554–3558. 2010.PubMed/NCBI | |
|
Morimatsu K, Aishima S, Yamamoto H, Hayashi A, Nakata K and Oda Y, Shindo K, Fujino M, Tanaka M and Oda Y: Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm. Hum Pathol. 44:1714–1721. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Xie Y, Li X, Gu L, Gao Y, Tang L, Chen J and Zhang X: Prognostic value of high IMP3 expression in solid tumors: A meta-analysis. Onco Targets Ther. 10:2849–2863. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, et al: Cyclin E overexpression and amplification in human tumours. J Pathol. 200:375–382. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lugli A, Forster Y, Haas P, Nocito A, Bucher C, Bissig H, Mirlacher M, Storz M, Mihatsch MJ and Sauter G: Calretinin expression in human normal and neoplastic tissues: A tissue microarray analysis on 5233 tissue samples. Hum Pathol. 34:994–1000. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, et al: Prevalence of KIT expression in human tumors. J Clin Oncol. 22:4514–4522. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Minner S, Luebke AM, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G and Wilczak W: High level of Ets-related gene expression has high specificity for prostate cancer: A tissue microarray study of 11 483 cancers. Histopathology. 61:445–453. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Andersen CL, Monni O, Wagner U, Kononen J, Bärlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, et al: High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol. 161:73–79. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Almanzar G, Olkhanud PB, Bodogai M, Dell'agnola C, Baatar D, Hewitt SM, Ghimenton C, Tummala MK, Weeraratna AT, Hoek KS, et al: Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells. Clin Cancer Res. 15:1954–1963. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Erez A, Perelman M, Hewitt SM, Cojacaru G, Goldberg I, Shahar I, Yaron P, Muler I, Campaner S, Amariglio N, et al: Sil overexpression in lung cancer characterizes tumors with increased mitotic activity. Oncogene. 23:5371–5377. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Geiszt M, Lekstrom K, Brenner S, Hewitt SM, Dana R, Malech HL and Leto TL: NAD(P)H oxidase 1, a product of differentiated colon epithelial cells, can partially replace glycoprotein 91phox in the regulated production of superoxide by phagocytes. J Immunol. 171:299–306. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Dicken BJ, Graham K, Hamilton SM, Andrews S, Lai R, Listgarten J, Jhangri GS, Saunders LD, Damaraju S and Cass C: Lymphovascular invasion is associated with poor survival in gastric cancer: An application of gene-expression and tissue array techniques. Ann Surg. 243:64–73. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mirlacher M, Kasper M, Storz M, Knecht Y, Dürmüller U, Simon R, Mihatsch MJ and Sauter G: Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol. 17:1414–1420. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, Odunsi K and Cheney RT: IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol. 133:899–908. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE and Jiang Z: The oncofetal protein IMP3: A novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 32:304–315. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yi X and Zheng W: Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol. 20:20–25. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, et al: Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: Diagnostic significance and clinicopathologic correlations. Mod Pathol. 20:1263–1268. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kazeminezhad B, Mirafsharieh SA, Dinyari K, Azizi D and Ebrahimi A: Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases. Turk J Gastroenterol. 25:253–256. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Feng W, Zhou Z, Peters JH, Khoury T, Zhai Q, Wei Q, Truong CD, Song SW and Tan D: Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions. Arch Pathol Lab Med. 135:1024–1031. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
He Y, Li L, Jiang W, Wang DQ, Xu L, Huang Q, Zhang Y and Yang KX: Expression of the insulin-like growth factor-II mRNA-binding protein 3 (IMP3) and carcinoembryonic antigen (CEA) in mucinous minimal deviation adenocarcinoma. Pathol Res Pract. 207:295–299. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wachter DL, Schlabrakowski A, Hoegel J, Kristiansen G, Hartmann A and Riener MO: Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. Am J Surg Pathol. 35:873–877. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Zhang J, Wang Y, Zheng L, Lin Z and Cai Y: Expression of insulin-like growth factor 2 mRNA-binding protein 3 expression and analysis of prognosis in the patients with lung squamous cell carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 29:694–697. 2013.(In Chinese). PubMed/NCBI | |
|
Perak R Beljan, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V and Peric M: IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol. 7:1652012. View Article : Google Scholar : PubMed/NCBI | |
|
Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL and Xu H: IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol. 41:477–484. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen ST, Jeng YM, Chang CC, Chang HH, Huang MC, Juan HF, Hsu CH, Lee H, Liao YF, Lee YL, et al: Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma. Cancer Sci. 102:2191–2198. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Takata A, Takiguchi S, Okada K, Takahashi T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Mori M and Doki Y: Expression of insulin-like growth factor-II mRNA-binding protein-3 as a marker for predicting clinical outcome in patients with esophageal squamous cell carcinoma. Oncol Lett. 8:2027–2031. 2014.PubMed/NCBI | |
|
King RL, Pasha T, Roullet MR, Zhang PJ and Bagg A: IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Hum Pathol. 40:1699–1705. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Gaete S: Consciousness as meaning. Actas Luso Esp Neurol Psiquiatr. 28:306–330. 1969.(In Spanish). PubMed/NCBI | |
|
Minato H, Kurose N, Fukushima M, Nojima T, Usuda K, Sagawa M, Sakuma T, Ooi A, Matsumoto I, Oda M, et al: Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells. Am J Clin Pathol. 141:85–93. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shi J, Liu H, Wang HL, Prichard JW and Lin F: Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder. Hum Pathol. 44:503–511. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yu L, Xu H, Wasco MJ, Bourne PA and Ma L: IMP-3 expression in melanocytic lesions. J Cutan Pathol. 37:316–322. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Elshafey MR, Ahmed RA, Mourad MI and Gaballah ET: The oncofetal protein IMP3 is an indicator of early recurrence and poor outcome in mucoepidermoid carcinoma of salivary glands. Cancer Biol Med. 13:286–295. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ismerim AB, Ferreira SV, Lessa AM, Júnior AS Pereira, Gurgel CA, Coutinho-Camillo CM, Soares FA, Vilas-Bôas DS, Vidal MT and Santos JN: Insulin-like growth factor ii messenger RNA-binding protein 3 in salivary gland tumors. Appl Immunohistochem Mol Morphol. 24:422–426. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chisté M, Alexis J and Recine M: IMP3 expression in serous tumors of the ovary. Appl Immunohistochem Mol Morphol. 22:658–662. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hu S, Wu X, Zhou B, Xu Z, Qin J, Lu H, Lv L, Gao Y, Deng L, Yin J, et al: IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 140:883–893. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wachter DL, Kristiansen G, Soll C, Hellerbrand C, Breuhahn K, Fritzsche F, Agaimy A, Hartmann A and Riener MO: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology. 60:278–286. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Soddu S, Di Felice E, Cabras S, Castellanos ME, Atzori L, Faa G and Pilloni L: IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: An immunohistochemical study. Eur J Histochem. 57:e62013. View Article : Google Scholar : PubMed/NCBI | |
|
Denby KS, Briones AJ, Bourne PA, Spaulding BO, Lu D, Fischer-Colbrie R, Qu Z, Wang HL and Xu H: IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver. Appl Immunohistochem Mol Morphol. 20:573–579. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Rock KL, Woda BA, Jiang Z, Fraire AE and Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: An immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 20:242–247. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kumara H Shantha, Kirchoff D, Caballero OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ, Cordon-Cardo C, et al: Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. Oncoscience. 2:607–614. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, et al: Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer. 48:3405–3413. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Wang P, Li Z, Xu W, Dai L, Wang K and Zhang J: Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol. 69:57–63. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Barton VN, Donson AM, Birks DK, Kleinschmidt-DeMasters BK, Handler MH, Foreman NK and Rush SZ: Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma. J Neuropathol Exp Neurol. 72:442–449. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bellezza G, Prosperi E, Del Sordo R, Colella R, Rulli A and Sidoni A: IMP3 is strongly expressed in malignant phyllodes tumors of the breast: An immunohistochemical study. Int J Surg Pathol. 24:37–42. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL and Khan A: IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol. 40:1528–1533. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z and Kwon ED: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 112:1471–1479. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL and Jiang Z: IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 14:1701–1706. 2008. View Article : Google Scholar : PubMed/NCBI |
